RBC Capital Sticks to Its Hold Rating for Lennar (LEN)
RBC Capital analyst Michael Dahl maintained a Hold rating on Lennar (LEN – Research Report) today and set a price target of $125.00. The ...
RBC Capital Sticks to Its Buy Rating for AZEK Company (AZEK)
RBC Capital analyst Michael Dahl maintained a Buy rating on AZEK Company (AZEK – Research Report) yesterday and set a price target of $58.00.
Olin downgraded at RBC Capital Markets on shaky demand recovery
Financial-services firm RBC Capital Markets downgraded Olin (OLN) to Sector Perform due to delayed demand recovery, but ...
Hedge fund investors push for alternative trades in choppy markets, says Barclays
Investors, fearful of choppier markets in 2025, are again favouring alternative trades and moving away from hedge fund ...
FMC downgraded at RBC Capital; shares plunge on weak outlook
FMC (NYSE:FMC) on Wednesday was downgraded to Sector Perform from a previous investment rating of Outperform by analysts at ...
Hosted on MSN1y
Goldman Sachs and RBC Capital Markets top M&A financial advisers in oil and gas sector in 2023
RBC Capital Markets advised on a total of 34 deals ... Evercore was third with 19, Barclays came fourth with 18 and Goldman Sachs secured fifth spot with 16 deals. GlobalData’s league tables ...
Investing6d
RBC Capital Markets initiates Greencore coverage with 'outperform' rating
Investing.com -- RBC Capital Markets has initiated coverage on Greencore Group (LON:GNC) with an 'outperform' rating, citing the company's improving profitability, growth initiatives, and ...
The TRADE21d
RBC Capital Markets names new head of European and Asian product, multi-asset agency solutions
RBC Capital Markets has promoted Adam Ragol-Levy to head of European and Asian product, multi-asset agency solutions. The appointment follows three years serving as global multi-asset product manager ...
Investing8d
RBC Capital Markets upgrades EssilorLuxottica citing growth potential
Investing.com -- RBC Capital Markets has upgraded EssilorLuxottica (EPA:ESLX) to "outperform," citing strong fundamentals and growth opportunities in the ophthalmology sector. Shares of the ...